| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
167,290,000 |
| Market
Cap: |
189.04(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6061 - $2.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile X4 Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary product candidate is mavorixafor, a small molecule chemokine receptor type 4 (CXCR4) antagonist that inhibits receptor binding by CXCL12, the cognate ligand of CXCR4. Co. is conducting clinical trials of mavorixafor: for the treatment of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis syndrome, a rare primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene; and in people with chronic neutropenia and Waldenstrom's macroglobulinemia, a rare B-cell lymphoproliferative disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
25,000 |
25,000 |
| Total Buy Value |
$0 |
$0 |
$29,875 |
$29,875 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
185,708 |
185,708 |
353,799 |
624,831 |
| Total Sell Value |
$170,713 |
$170,713 |
$383,960 |
$557,665 |
| Total People Sold |
4 |
4 |
5 |
6 |
| Total Sell Transactions |
8 |
8 |
19 |
42 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Taveras Arthur |
Chief Scientific Officer |
• – – |
2024-03-11 |
4 |
S |
$0.88 |
$12,552 |
D/D |
(14,235) |
234,301 |
|
-24% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2024-03-11 |
4 |
S |
$0.88 |
$46,347 |
D/D |
(52,500) |
0 |
|
-24% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2024-03-11 |
4 |
S |
$0.88 |
$13,591 |
D/D |
(15,409) |
291,752 |
|
-24% |
|
| Ragan Paula |
President and CEO |
• • – |
2024-03-11 |
4 |
S |
$0.88 |
$43,856 |
D/D |
(49,678) |
765,068 |
|
-24% |
|
| Taveras Arthur |
Chief Scientific Officer |
• – – |
2024-02-12 |
4 |
S |
$1.01 |
$793 |
D/D |
(787) |
248,536 |
|
-11% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2024-02-12 |
4 |
S |
$1.01 |
$3,709 |
D/D |
(3,683) |
307,161 |
|
-11% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2024-02-12 |
4 |
AS |
$1.01 |
$27,973 |
D/D |
(27,721) |
52,500 |
|
24% |
|
| Ragan Paula |
President and CEO |
• • – |
2024-02-12 |
4 |
AS |
$1.01 |
$21,892 |
D/D |
(21,695) |
814,746 |
|
24% |
|
| Ragan Paula |
President and CEO |
• • – |
2023-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
532,081 |
1,075,878 |
|
- |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2023-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
230,645 |
378,539 |
|
- |
|
| Baldry Mark |
Chief Commercial Officer |
• – – |
2023-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
34,947 |
34,947 |
|
- |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2023-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
230,645 |
310,866 |
|
- |
|
| Taveras Arthur |
Chief Scientific Officer |
• – – |
2023-10-31 |
4 |
A |
$0.00 |
$0 |
D/D |
230,645 |
317,018 |
|
- |
|
| Woods Keith |
Director |
– • – |
2023-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
90,000 |
|
- |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2023-09-08 |
4 |
AS |
$1.25 |
$3,300 |
D/D |
(2,642) |
147,894 |
|
-37% |
|
| Wyzga Michael S |
Director |
– • – |
2023-08-18 |
4 |
B |
$1.20 |
$29,875 |
D/D |
25,000 |
76,667 |
2.39 |
-25% |
|
| Stewart Murray |
Interim Chief Medical Officer |
• • – |
2023-08-10 |
4 |
S |
$1.06 |
$137,859 |
D/D |
(130,056) |
146,504 |
|
34% |
|
| Stewart Murray |
Interim Chief Medical Officer |
• • – |
2023-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
269,893 |
276,560 |
|
- |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2023-06-30 |
4 |
AS |
$1.89 |
$4,991 |
D/D |
(2,641) |
80,221 |
|
-58% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2023-06-30 |
4 |
AS |
$1.89 |
$877 |
D/D |
(464) |
150,536 |
|
-58% |
|
| Mostafa Adam S. |
Chief Financial Officer |
• – – |
2023-06-23 |
4 |
AS |
$1.93 |
$10,455 |
D/D |
(5,417) |
82,862 |
|
-59% |
|
| Ragan Paula |
President and CEO |
• • – |
2023-06-23 |
4 |
AS |
$1.92 |
$12,910 |
D/D |
(6,724) |
543,797 |
|
-59% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2023-06-23 |
4 |
AS |
$1.93 |
$1,654 |
D/D |
(857) |
151,000 |
|
-59% |
|
| Ragan Paula |
President and CEO |
• • – |
2023-06-15 |
4 |
AS |
$2.23 |
$14,995 |
D/D |
(6,724) |
550,521 |
|
-64% |
|
| Dibiase Mary |
Chief Operating Officer |
• – – |
2023-06-15 |
4 |
AS |
$2.23 |
$1,911 |
D/D |
(857) |
151,857 |
|
-64% |
|
160 Records found
|
|
Page 1 of 7 |
|
|
0.16 (12.4%) 
